BLA 761148 · Spectrum Pharms
Rolvedon
Eflapegrastim-Xnst · Subcutaneous · Leukocyte Growth Factor
NovelCDER novel approval, Sep 9, 2022: To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia
Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Sep 9, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
2 Phase 3, 1 recruiting
FAERS reports
30
16 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 18, 2026.
Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. Rolvedon is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. ( 1 ) Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. ( 1 )
Mechanism: Eflapegrastim-xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration and survival.
Therapeutic areas: Oncology · Hematology and blood cancers · Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ROLVEDON · EFLAPEGRASTIM-XNST 13.2MG/0.6ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Eflapegrastim" as an intervention, any sponsor and status, largest first.
- SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)Pivotal-lookingCompleted
Spectrum Pharmaceuticals, IncIndustry
NCT02643420 · 406 participants · Start Jan 19, 2016 · Primary completion Jan 24, 2018
Drug: SPI-2012; Pegfilgrastim and 2 more · For: Neutropenia; Breast Cancer
Sites: Glendale, Arizona; Tucson, Arizona; Yuma, Arizona · 81 sites in all
- SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and CyclophosphamidePivotal-lookingCompleted
Spectrum Pharmaceuticals, IncIndustry
NCT02953340 · 237 participants · Start May 10, 2017 · Primary completion Jun 8, 2018
Drug: SPI-2012; Pegfilgrastim and 2 more · For: Neutropenia; Breast Cancer
Sites: Tucson, Arizona; Yuma, Arizona; Hot Springs, Arkansas · 74 sites in all
- Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast CancerPivotal-lookingCompleted
Spectrum Pharmaceuticals, IncIndustry
NCT01724866 · 148 participants · Start Mar 25, 2013 · Primary completion Aug 12, 2014
Drug: SPI-2012; Pegfilgrastim and 2 more · For: Neutropenia
Sites: Glendale, Arizona; Scottsdale, Arizona; Fresno, California · 27 sites in all
- Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After ChemotherapyPivotal-lookingStatus unknown
Eunseong Medical Foundation Good GANG-AN HOSPITALAcademic, hospital or other
NCT05949333 · 100 participants (planned) · Start Nov 7, 2023 · Primary completion Jan 2025
Drug: Eflapegrastim · For: Breast Neoplasms
Sites: Busan, South Korea
Hanmi Pharmaceutical Company LimitedIndustry
NCT01037543 · 84 participants · Start Nov 2009 · Primary completion Feb 2011
Drug: HM10460A or placebo or Neulasta · For: Healthy
Sites: California City, California
Spectrum Pharmaceuticals, IncIndustry
NCT04187898 · 59 participants · Start Mar 11, 2020 · Primary completion Jul 16, 2024
Drug: Eflapegrastim; Eflapegrastim and 4 more · For: Neutropenia; Breast Cancer
Sites: Tucson, Arizona; Yuma, Arizona; Anaheim, California · 8 sites in all
Spectrum Pharmaceuticals, IncIndustry
NCT04570423 · 40 participants (planned) · Start May 20, 2021 · Primary completion Oct 2027
Drug: Eflapegrastim; Chemotherapy · For: Solid Tumors; Lymphoma
Sites: Valhalla, New York; Charlotte, North Carolina; Cleveland, Ohio · 5 sites in all
Hanmi Pharmaceutical Company LimitedIndustry
NCT00998283 · 40 participants · Start Oct 2009 · Primary completion Sep 2010
Drug: HM10460A 5μg/kg; HM10460A 15μg/kg and 4 more · For: Healthy
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- white blood cell count increased4
- asthenia3
- diarrhoea3
- leukocytosis3
- off label use3
- abdominal pain2
- accidental exposure to product2
- bone pain2
- constipation2
- fatigue2
- febrile neutropenia2
- nausea2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 13 |
| 2025 | 10 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rolvedon (Eflapegrastim-Xnst)
2024 spending
$1.6M
Beneficiaries
100
345 claims
Per beneficiary
$16,237
$7,197.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $661,601 |
| 2024 | $1,623,717 |
Part B: Rolvedon (Eflapegrastim-Xnst) · HCPCS J1449
2024 spending
$73.8M
Beneficiaries
6,293
21,515 claims
Per beneficiary
$11,721
2024 ASP limit $26.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $52,360,428 |
| 2024 | $73,760,786 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
Barrett JA, Greene D, Lakshmikanthan S, et al. · J Clin Pharmacol 2021 · Clinical Trial, Phase III, Multicenter Study
- A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Cobb PW, Moon YW, Mezei K, et al. · Cancer Med 2020 · Clinical Trial, Phase III, Comparative Study
- A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects.
Jeon Y, Lee N, Baek S, et al. · Drugs R D 2022 · Clinical Trial, Phase I, Randomized Controlled Trial
- Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Schwartzberg LS, Bhat G, Peguero J, et al. · Oncologist 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies.
Moon YW, Kim SK, Lee KS, et al. · Cancer Res Treat 2023 · Equivalence Trial
- An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Vacirca JL, Chan A, Mezei K, et al. · Cancer Med 2018 · Comparative Study, Controlled Clinical Trial
Sponsor: Spectrum Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.